Get the Stockscreener App
139.63
0.14%
-0.0763
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $139.63, with a volume of 642.81K.
It is down -0.14% in the last 24 hours and down -3.07% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$139.71
Open:
$139.24
24h Volume:
642.81K
Relative Volume:
0.09
Market Cap:
$173.41B
Revenue:
$29.45B
Net Income/Loss:
$8.51B
P/E Ratio:
20.59
EPS:
6.7823
Net Cash Flow:
$9.46B
1W Performance:
+2.33%
1M Performance:
-3.07%
6M Performance:
+22.83%
1Y Performance:
+30.08%
1-Day Range:
$138.85
$140.71
1-Week Range:
$137.17
$141.49
52-Week Range:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
139.71 | 173.41B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
924.53 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
241.76 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.83 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.88 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.47 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD? - TIKR.com
Cantor Fitzgerald reiterates Gilead Sciences stock rating at overweight By Investing.com - Investing.com India
Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kelleher Financial Advisors Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Meridian Investment Counsel Inc. Has $3.94 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Perpetual Ltd Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets - Yahoo Finance
Gilead Sciences, Inc. (GILD) Galapagos NV,M&A CallSlideshow (NASDAQ:GILD) 2026-04-03 - Seeking Alpha
Gilead Sciences, Inc. $GILD Position Reduced by Aberdeen Group plc - MarketBeat
Layoff Tracker: Gilead Lays Off Employees at California Headquarters - BioSpace
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Gilead Sciences, Inc. (GILD.NE) recent insider transactions - Yahoo Finance UK
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
Gilead Refuses to Sell Groundbreaking HIV Prevention Drug to MSF - marketscreener.com
HF Advisory Group LLC Buys 13,212 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
MSF Seeks Access to Breakthrough HIV Drug, But Gilead Refuses - allAfrica.com
Africa: Gilead Under Fire for Not Selling HIV Drug Lenacapavir to MSF - allAfrica.com
A Healthy Return: Drug Spin-off Nets Keymed Up To $320M - Benzinga
Bank Pictet & Cie Europe AG Purchases 136,605 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Banque Pictet & Cie SA Purchases 142,543 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Allspring Global Investments Holdings LLC Purchases 71,872 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
A Look At Gilead Sciences (GILD) Valuation After Recent Mixed Share Price Performance - Yahoo Finance
Nomura VIP Core Equity Series's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead to acquire Ouro Medicines in $2.18B deal, expand inflammation pipeline - MSN
Morgan Stanley Reaffirms Overweight on Gilead Sciences, Inc. (GILD), Citing LEN Potential - MSN
Gilead extends Arcellx tender offer expiration date - MSN
Gilead (NASDAQ: ACLX) extends $115 per‑share tender, CVR pays $5 on condition - Stock Titan
Gilead Extends Tender Offer to Acquire Arcellx - Yahoo Finance
Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer - ACCESS Newswire
Gilead Sciences's Q1 2026 Earnings: What to Expect - Yahoo Finance
Gilead Sciences Inc Stock (GILD) Moved Up by 3.03% on Apr 1: Facts Behind the Movement - TradingKey
Gilead Sciences, Inc. $GILD Shares Acquired by Moody Lynn & Lieberson LLC - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Raised by Nisa Investment Advisors LLC - MarketBeat
Meyer Handelman Co. Has $41.33 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Shrier Wealth Management LLC Buys Shares of 14,244 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution - FinancialContent
Gilead Sciences Inc. stock rises Tuesday, still underperforms market - MarketWatch
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $160 - Moomoo
UBS reiterates Gilead Sciences stock rating on strong Yeztugo sales - Investing.com
Gilead Sciences Inc Stock (GILD) Moved Up by 3.62% on Mar 31: A Full Analysis - TradingKey
Gilead and its new HIV prevention drug are in the sights of a well-known humanitarian group - The Business Journals
MSF denied access to Gilead HIV-prevention drug - EU Reporter
J. Safra Sarasin Holding AG Trims Gilead Sciences Stake - National Today
Gilead (GILD) Enters Agreement to Acquire Ouro Medicines - GuruFocus
Gilead Sciences, Inc. $GILD Shares Bought by Mn Services Vermogensbeheer B.V. - MarketBeat
Boston Common Asset Management LLC Sells 15,833 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration - Yahoo Finance
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Biotech deal-O-rama, Gilead and Tallon’s U.K. vision — a BioCentury podcast - biocentury.com
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):